PTC Therapeutics | PTCT - Net Income

Stock Price
73.63
Daily Change
-1.20 -1.60%
Monthly
-4.08%
Yearly
47.29%
Q1 Forecast
73.20

PTC Therapeutics reported $15.9M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025
Xencor USD -6.03M 24.8M Sep/2025